Is Liver Transplantation Appropriate for Patients with Potentially Resectable De Novo Hilar Cholangiocarcinoma?

2015 ◽  
Vol 221 (1) ◽  
pp. 130-139 ◽  
Author(s):  
Kristopher P. Croome ◽  
Charles B. Rosen ◽  
Julie K. Heimbach ◽  
David M. Nagorney
2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Naruki Higashidate ◽  
Suguru Fukahori ◽  
Shinji Ishii ◽  
Nobuyuki Saikusa ◽  
Naoki Hashizume ◽  
...  

Abstract Background Apart from Kasai’s procedure, liver transplantation (LTx) has dramatically improved the outcome of children with biliary atresia (BA). However, de novo malignancy has been reported to be one of the major causes of late mortality after LTx among adults. We report a rare case of de novo gastric cancer developing after LTx for BA received during childhood. Case presentation A 21-year-old male patient who had undergone LTx for BA at age 2 years occasionally visited our outpatient clinic due to symptoms of epigastric pain and dysphagia. Endoscopic examination and computed tomography revealed advanced gastric cancer at the gastroesophageal junction with multiple liver metastases. Despite systemic chemotherapy, the disease progressed, resulting in patient’s death 2 years after the diagnosis. Conclusions De novo malignancy in the absence of post-transplant lymphoproliferative disease is rare in pediatric patients who received LTx. To the best of our knowledge, no report has been available on the development of gastric cancer after LTx for BA during childhood. Primary physicians should therefore establish a follow-up plan for patients receiving LTx for BA considering the potential for the development of de novo malignancy, including gastric cancer, despite its rarity.


2009 ◽  
Vol 41 (4) ◽  
pp. 1303-1305 ◽  
Author(s):  
U. Baccarani ◽  
G.L. Adani ◽  
D. Serraino ◽  
D. Lorenzin ◽  
M. Gambato ◽  
...  

2012 ◽  
Vol 94 (10S) ◽  
pp. 602
Author(s):  
M. G. Fernandez ◽  
D. Loredo ◽  
F. Gruz ◽  
S. Raffa ◽  
S. Yantorno ◽  
...  

2005 ◽  
Vol 55 (10) ◽  
pp. 660-664 ◽  
Author(s):  
Andrew P. Keaveny ◽  
Fredric D. Gordon ◽  
Urmila Khettry

2021 ◽  
Vol 13 (12) ◽  
pp. 1991-2004
Author(s):  
Ma Ai Thanda Han ◽  
Raquel Olivo ◽  
Catherine J Choi ◽  
Nikolaos Pyrsopoulos

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 92
Author(s):  
Palittiya Sintusek ◽  
Supranee Buranapraditkun ◽  
Piyaporn Wanawongsawad ◽  
Nawarat Posuwan ◽  
Pattarawat Thantiworasit ◽  
...  

A high prevalence of hepatitis B (HepB) antibody loss after liver transplantation (LT) and de novo HepB infection (DNH) was documented, hence revaccination to prevent DNH is crucial. This study aimed to compare the safety and immunogenicity of two HepB vaccine regimens in liver-transplanted children. Liver-transplanted children who were previously immunised but showed HepB surface antibodies (anti-HBs) ≤ 100 mIU/mL were randomised to receive a standard three-dose (SD) and double three-dose (DD) vaccine intramuscularly in months 0–1–6. Anti-HBs and T-cell-specific response to the HepB antigen were assessed. A total of 61 children (54.1% male, aged 1.32 ± 1.02 years) completed the study without any serious adverse reaction. The seroprotective rate was 69.6% vs. 60% (p = 0.368) and 91.3% vs. 85% (p = 0.431) in SD and DD after the first and third 3-dose vaccinations, respectively. The geometric mean titre (95% confidence interval) of anti-HBs in SD and DD were 443.33 (200.75–979.07) vs. 446.17 (155.58–1279.50) mIU/mL, respectively, at completion. Numbers of interferon-γ-secreting cells were higher in hyporesponders/responders than in nonresponders (p = 0.003). The significant factors for the immunologic response to HepB vaccination were anti-HB levels prevaccination, tacrolimus trough levels, and time from LT to revaccination. SD and DD had comparative immunogenicity and were safe for liver-transplanted children who were previously immunised.


Sign in / Sign up

Export Citation Format

Share Document